Basit öğe kaydını göster

dc.contributor.authorUlas, Burak
dc.contributor.authorAltan-Yaycioglu, Rana
dc.contributor.authorBal, Nebil
dc.date.accessioned2019-05-06T12:54:56Z
dc.date.available2019-05-06T12:54:56Z
dc.date.issued2018
dc.identifier.issn2222-3959
dc.identifier.urihttp://www.ijo.cn/gjyken/ch/reader/view_abstract.aspx?file_no=20180703&flag=1
dc.identifier.urihttp://hdl.handle.net/11727/3195
dc.description.abstractAIM: To evaluate the inhibitory effect of subconjunctival bevacizumab as single- and multiple-dose application, and compare their effects on corneal neovascularization in a rat model. METHODS: Thirty adult Sprague-Dawley rats were used in this experimental study. The central cornea of the rats was cauterized chemically. The rats were randomly enrolled into three groups. All groups received subconjunctival injections. In Group 1 (control group, n=10), 0.05 mL 0.9% NaCl solution was injected on the first day. In Group 2 (single-dose group, n=10), 0.05 mL bevacizumab (1.25 mg) was injected on the first day. In Group 3 (multiple-dose group, n=10), four doses of 0.05 mL bevacizumab (1.25 mg) were injected on the first, third, fifth and seventh day. Slit-lamp examination of all rats was performed at the third and ninth day. Digital images of the corneas were taken and analyzed using image analysis software to calculate corneal neovascularization area. All rats were sacrificed on the tenth day. In corneal sections, the number of blood vessels, state of inflammation and collagen formation was evaluated histopathologically. RESULTS: In Group 3, corneal edema grades were significantly lower than Group 1 and Group 2 (P=0.02, and P=0.035, respectively). The mean percentage of neovascularized corneal area in Group 3 was significantly lower than Group 2 (P=0.005). On histopathological examination, Group 2 and Group 3 showed significantly less number of blood vessels than Group 1 (P=0.005, and P=0.001, respectively). Additionally, Group 3 showed significantly less number of blood vessels compared to Group 2 (P=0.019). Inflammation and edema grades were significantly lower in Group 3 compared to Group 1 (P=0.001). CONCLUSION: Subconjunctival bevacizumab injection is effective in inhibition of newly formed corneal neovascularization. The multiple-dose bevacizumab treatment seems to be more effective compared to single-dose treatment.en_US
dc.language.isoengen_US
dc.relation.isversionof10.18240/ijo.2018.07.03en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCorneaen_US
dc.subjectCorneal neovascularizationen_US
dc.subjectBevacizumaben_US
dc.subjectİnflammationen_US
dc.subjectRaten_US
dc.titleComparison of the inhibitory effect of different doses of subconjunctival bevacizumab application in an experimental model of corneal neovascularizationen_US
dc.typearticleen_US
dc.relation.journalINTERNATIONAL JOURNAL OF OPHTHALMOLOGYen_US
dc.identifier.volume11en_US
dc.identifier.issue7en_US
dc.identifier.startpage1090en_US
dc.identifier.endpage1095en_US
dc.identifier.wos000438930100003en_US
dc.identifier.scopus2-s2.0-85050319609en_US
dc.contributor.pubmedID30046522en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.contributor.researcherIDAAG-3306-2019en_US
dc.contributor.researcherIDAAL-4440-2020en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster